机译:PCSK9抑制剂Evolocumab在患有糖尿病患者的心血管安全性和疗效以及Evolocumab对糖尿病的影响以及新出病糖尿病的风险:傅里叶随机对照试验的预先分析
TIMI Study Group Division of Cardiovascular Medicine Brigham and Women's Hospital and Harvard;
Li Ka Shing Knowledge Institute of St Michael's Hospital University of Toronto;
TIMI Study Group Division of Cardiovascular Medicine Brigham and Women's Hospital and Harvard;
TIMI Study Group Division of Cardiovascular Medicine Brigham and Women's Hospital and Harvard;
UCSF Fresno;
Department of Molecular Medicine University of Pavia and Cardiac Intensive Care Unit and;
TIMI Study Group Division of Cardiovascular Medicine Brigham and Women's Hospital and Harvard;
TIMI Study Group Division of Cardiovascular Medicine Brigham and Women's Hospital and Harvard;
Polyclinic for Endocrinology Diabetes and Preventive Medicine University of Cologne;
Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine Technion-IIT;
Metabolic Institute of America;
Amgen;
Amgen;
Sydney Medical School NHMRC Clinical Trials Centre University of Sydney;
International Centre for Circulatory Health National Heart and Lung Institute Imperial College;
Oslo University Hospital Ullev?l and Medical Faculty University of Oslo;
机译:PCSK9抑制剂Evolocumab在患有糖尿病患者的心血管安全性和疗效以及Evolocumab对糖尿病的影响以及新出病糖尿病的风险:傅里叶随机对照试验的预先分析
机译:AliroCumab对患者患者急性冠状动脉综合征或患者糖尿病患者心血管和代谢结果的影响
机译:Alirocumab对患者患者急性冠状动脉综合征或没有糖尿病患者急性冠状动脉综合征后的心血管和代谢结果的影响
机译:evolocumab抑制前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型(PCSK9):强大的低密度脂蛋白胆固醇(LDL-C)降低并改善了心血管预后而没有增加患糖尿病的风险
机译:pCsK9抑制剂evolocumab对糖尿病患者和非糖尿病患者的心血管安全性和疗效以及evolocumab对血糖和新发糖尿病风险的影响:对FOURIER随机对照试验的预先分析。